Evidence map›Paper›PMID 41482623›Full record

Trial reportSubstance use & addiction journal2026

Factors Associated With Opioid-Involved Overdose: Descriptive Data From a Randomized Controlled Trial Evaluating Extended-Release Buprenorphine for Perinatal Opioid Use Disorder.

Sara M Witcraft, Leah Holcomb, Yingjia Wei, Gerald Cochran, John T Winhusen, Michelle R Lofwall, Peter R Martin, Jessica L Young, Jessica Spinali, Constance Guille

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Substance use & addiction journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sara M WitcraftDepartment of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0001-8890-0465
Leah HolcombDepartment of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0002-3869-4891
Yingjia WeiPopulation Health Sciences Department, University of Utah, Salt Lake City, UT, USA.
Gerald CochranDepartment of Internal Medicine, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-0153-0252
John T WinhusenDepartment of Psychiatry and Behavioral Neuroscience, College of Medicine, University of Cincinnati, OH, USA.
Michelle R LofwallPsychiatry and Behavioral Sciences, Center on Drug and Alcohol Research, College of Medicine, University of Kentucky, Lexington, KY, USA.
Peter R MartinPsychiatry and Behavioral Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA.
Jessica L YoungPsychiatry and Behavioral Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA.
Jessica SpinaliHOPE Clinic, Department of Obstetrics & Gynecology, Massachusetts General Hospital, Boston, MA, USA.
Constance GuilleDepartment of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.

Funding

The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
Southern Consortium Node of the Clinical Trials Network (Varenicline)UG1DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KATHLEEN T. BRADY, Kelly S. Barth · 2015 to 2026
$24.8M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
Greater Intermountain Node (CTN-0151)UG1DA049444 · NIDA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Gerald T. Cochran, Gerald T. Cochran · 2019 to 2026
$16.8M
Southwest Clinical Trials Node: Clinical Research and Practice to Address Substance Use in Diverse, Rural, and Underserved PopulationsUG1DA049468 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI MARIA ADELA GRANDO, Kimberly Page · 2019 to 2026
$12.5M
Project-008UG1DA049436 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jane M. Liebschutz, Erin L Winstanley · 2019 to 2026
$10.5M
NIDA NIH HHS HHSN271201400028CNIDA NIH HHS HHSN271201500065CNIDA NIH HHS UG1 DA013714NIDA NIH HHS UG1 DA013720NIDA NIH HHS UG1 DA013727NIDA NIH HHS UG1 DA013732NIDA NIH HHS UG1 DA015815NIDA NIH HHS UG1 DA015831NIDA NIH HHS UG1 DA049436NIDA NIH HHS UG1 DA049444NIDA NIH HHS UG1 DA049468
6 · The paper itself

Abstract

backgroundOpioid use disorder (OUD) during pregnancy is a leading contributor to peripartum morbidity and mortality, with overdose deaths rising significantly in recent years. Despite the identification of various factors associated with overdose events, including social, demographic, psychiatric, and neonatal outcomes, the relative contributions of these factors to peripartum overdose history (or lack thereof) remain unclear. Thus, this study aims to characterize factors associated with lifetime opioid-involved overdose events among currently pregnant individuals receiving buprenorphine (BUP) treatment for OUD.

methodsTreatment-seeking pregnant individuals with an estimated gestational age of 6 to 30 weeks were enrolled in a large multisite randomized controlled trial evaluating 2 BUP formulations for OUD. Participant baseline demographic, substance use, and mental health data were collected using validated measures, and random forest modeling identified key factors associated with lifetime opioid overdose events.

resultsThe 140 pregnant participants (

conclusionsThese findings underscore the critical need to address substance use, co-occurring mental health, and socioeconomic challenges that are associated with previous opioid overdose. Identifying and targeting key modifiable overdose risk factors can inform the development of tailored interventions to improve outcomes for this population.

Indexed as

Analgesics, OpioidBuprenorphineDrug OverdoseNarcotic AntagonistsOpiate OverdoseOpiate Substitution TreatmentOpioid-Related DisordersPregnancy ComplicationsAdultDelayed-Action PreparationsFemaleHumansPregnancyRisk FactorsAnalgesics, OpioidBuprenorphineDelayed-Action PreparationsNarcotic Antagonistsopioid overdoseopioid use disorderpregnancy

Identifiers

PMID41482623
PMCPMC13085863

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.